Fortrea Holdings Inc. (FTRE)

Fortrea Holdings' stock price has experienced volatility in the past six months. In August 2025, Fortrea Holdings Inc. increased its earnings guidance for the full year 2025. In September 2025, William Sharbaugh was appointed to its Board of Directors. In October 2025, the company announced a tender offer for outstanding debt. In November 2025, Fortrea reported third-quarter 2025 results, with revenue beating expectations but non-GAAP profit falling below consensus estimates. In December 2025, analyst rating changes occurred, with upgrades from Barclays and Citigroup, and a downgrade from Robert W. Baird. In January 2026, Fortrea announced its participation in the J.P. Morgan Healthcare Conference and the date for its fourth quarter and full year 2025 financial results conference call, and analyst upgrades from Truist and Evercore ISI also took place. In February 2026, the stock price was $14.65.

Fortrea Holdings has experienced a struggle in consistently generating demand over the last four years, with sales declining at an annual rate of 2.6%. Analysts anticipate a further decline in revenue by 6.2% over the next 12 months, indicating expected demand headwinds for its products and services.

Fortrea Holdings, Inc. is a global contract research organization (CRO) formed in 2023 as a spin-off from Labcorp. It focuses on advancing life-changing therapies for biopharmaceutical, biotechnology, medical device, and diagnostic companies. The company provides comprehensive clinical development services, including early-phase development, clinical pharmacology, bioanalytical services, late-phase clinical trial management, and strategic regulatory consulting. Fortrea manages its business through a single segment, Clinical Services, and also has an Enabling Services segment that provides technology solutions. It focuses on therapeutic areas such as oncology, central nervous system disorders, neurodegenerative diseases, rare diseases, and cell and gene therapies.

Fortrea Holdings, Inc. operates in approximately 90 to 100 countries worldwide. The company maintains primary office locations in the United States, the United Kingdom, China, India, and Singapore, with additional field operations in various other jurisdictions.

Fortrea's brand reputation has faced challenges related to its historical practices, particularly concerning animal testing practices involving non-human primates.

Fortrea Holdings Inc. has a significant institutional ownership base, with 523 institutional owners and shareholders holding a total of 110,434,702 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Goldman Sachs Group Inc, IJR - iShares Core S&P Small-Cap ETF, Corvex Management LP, State Street Corp, Sessa Capital IM, L.P., Aqr Capital Management Llc, Fmr Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Charles Schwab Investment Management, Inc., and Deutsche Asset & Wealth Management.